{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:06:33Z","timestamp":1789005993091,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Shanxi General Surgery \"136\" Healthcare Engineering Project","award":["2024XYZ03"],"award-info":[{"award-number":["2024XYZ03"]}]},{"name":"the Basic Research Project of Shanxi Science and Technology Department","award":["202303021221190"],"award-info":[{"award-number":["202303021221190"]}]},{"name":"Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences) High-Level Research Achievement Continuation Funding Project","award":["2024GSPYJ03"],"award-info":[{"award-number":["2024GSPYJ03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04467-4","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:06:19Z","timestamp":1782435979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications"],"prefix":"10.1186","volume":"24","author":[{"given":"Ying","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"3","key":"4467_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834 . PubMed PMID: 38572751.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4467_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03502-3 . PubMed PMID: 39994475.","journal-title":"Nat Med"},{"issue":"3","key":"4467_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molonc","volume":"4","author":"B Weigelt","year":"2010","unstructured":"Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4(3):192\u2013208. https:\/\/doi.org\/10.1016\/j.molonc. 2010.04.004 PubMed PMID: 20452298; PubMed Central PMCID: PMC5527938.","journal-title":"Mol Oncol"},{"issue":"10074","key":"4467_CR4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet Lond Engl. 2017;389(10074):1134\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(. 16)31891-8 PubMed PMID: 27865536.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"4467_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4 . PubMed PMID: 39966355; PubMed Central PMCID: PMC11836418.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4467_CR6","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.3390\/ijms26083920","volume":"26","author":"Y Choi","year":"2025","unstructured":"Choi Y, Tan J, Lin D, Lee JS, Yuan Y. Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors. Int J Mol Sci. 2025;26(8):3920. https:\/\/doi.org\/10.3390\/ijms26083920 . PubMed PMID: 40332761; PubMed Central PMCID: PMC12027891.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4467_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.20892\/j.issn.2095-3941","volume":"22","author":"J Bai","year":"2025","unstructured":"Bai J, Gao Y, Zhang G. The treatment of breast cancer in the era of precision medicine. Cancer Biol Med. 2025;22(4):322\u201347. https:\/\/doi.org\/10.20892\/j.issn.2095-3941. 2024.0510 PubMed PMID: 40269562; PubMed Central PMCID: PMC12032834.","journal-title":"Cancer Biol Med"},{"issue":"2","key":"4467_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/cancers16020396","volume":"16","author":"D Narvaez","year":"2024","unstructured":"Narvaez D, Nadal J, Nervo A, Costanzo MV, Paletta C, Petracci FE, et al. The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review. Cancers. 2024;16(2):396. https:\/\/doi.org\/10.3390\/cancers16020396 . PubMed PMID: 38254885; PubMed Central PMCID: PMC10814091.","journal-title":"Cancers"},{"issue":"9","key":"4467_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24(9):629\u201346. https:\/\/doi.org\/10.1038\/s41568-024-00728-0 . PubMed PMID: 39117919.","journal-title":"Nat Rev Cancer"},{"issue":"6576","key":"4467_CR10","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419. https:\/\/doi.org\/10.1126\/science.abf. 9419 PubMed PMID: 34990248.","journal-title":"Science"},{"key":"4467_CR11","doi-asserted-by":"publisher","first-page":"1369626","DOI":"10.3389\/fimmu","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wu Y, Yan G, Zhang G. Tertiary lymphoid structures in cancer: maturation and induction. Front Immunol. 2024;15:1369626. https:\/\/doi.org\/10.3389\/fimmu. 2024.1369626 PubMed PMID: 38690273; PubMed Central PMCID: PMC11058640.","journal-title":"Front Immunol"},{"issue":"1","key":"4467_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9(1):225. https:\/\/doi.org\/10.1038\/s41392-024-01947-5 . PubMed PMID: 39198425; PubMed Central PMCID: PMC11358547.","journal-title":"Signal Transduct Target Ther"},{"issue":"7791","key":"4467_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8 . PubMed PMID: 31942071.","journal-title":"Nature"},{"issue":"Suppl 2","key":"4467_CR14","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.arbres","volume":"60","author":"M Xie","year":"2024","unstructured":"Xie M, Lin X, Bao X, Liang Y, Deng H, Song J, et al. Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer. Arch Bronconeumol. 2024;60(Suppl 2):S77\u201385. https:\/\/doi.org\/10.1016\/j.arbres. .2024.07.020 PubMed PMID: 39174437.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"4467_CR15","doi-asserted-by":"publisher","first-page":"e006425","DOI":"10.1136\/jitc-2022-006425","volume":"11","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang XY, Zuo JL, Wang XF, Feng XW, Zhang B, et al. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. J Immunother Cancer. 2023;11(2):e006425. https:\/\/doi.org\/10.1136\/jitc-2022-006425 . PubMed PMID: 36759015; PubMed Central PMCID: PMC9923349.","journal-title":"J Immunother Cancer"},{"key":"4467_CR16","doi-asserted-by":"publisher","first-page":"868155","DOI":"10.3389\/fimmu.2022.868155","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Liu J, Han Y, Deng Y, Li J, Jiang Y. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer. Front Immunol. 2022;13:868155. https:\/\/doi.org\/10.3389\/fimmu.2022.868155 . PubMed PMID: 35664009; PubMed Central PMCID: PMC9161084.","journal-title":"Front Immunol"},{"issue":"3","key":"4467_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","volume":"132","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu Y, Wang C, Jiang Z, Li J, Li X, et al. Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer. Br J Cancer. 2025;132(3):295\u2013310. https:\/\/doi.org\/10.1038\/s41416-024-02917-y . PubMed PMID: 39658606; PubMed Central PMCID: PMC11790963.","journal-title":"Br J Cancer"},{"issue":"23","key":"4467_CR18","doi-asserted-by":"publisher","first-page":"e42566","DOI":"10.1097\/MD.0000000000042566","volume":"104","author":"M Li","year":"2025","unstructured":"Li M, Cao J, Wang Y, Zhao Z, Ai L, Zhang K. Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer. Med (Baltim). 2025;104(23):e42566. https:\/\/doi.org\/10.1097\/MD.0000000000042566 . PubMed PMID: 40489875; PubMed Central PMCID: PMC12151043.","journal-title":"Med (Baltim)"},{"issue":"3","key":"4467_CR19","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1002\/mco2","volume":"5","author":"S Wang","year":"2024","unstructured":"Wang S, Wang H, Li C, Liu B, He S, Tu C. Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications. MedComm. 2024;5(3):e489. https:\/\/doi.org\/10.1002\/mco2. 489 PubMed PMID: 38469550; PubMed Central PMCID: PMC10925885.","journal-title":"MedComm"},{"key":"4467_CR20","doi-asserted-by":"publisher","first-page":"674375","DOI":"10.3389\/fimmu","volume":"12","author":"A Johansson-Percival","year":"2021","unstructured":"Johansson-Percival A, Ganss R. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling. Front Immunol. 2021;12:674375. https:\/\/doi.org\/10.3389\/fimmu. 2021.674375 PubMed PMID: 34122434; PubMed Central PMCID: PMC8191417.","journal-title":"Front Immunol"},{"issue":"3","key":"4467_CR21","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","volume":"36","author":"AB Rodriguez","year":"2021","unstructured":"Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 2021;36(3):109422. https:\/\/doi.org\/10.1016\/j.celrep.2021.109422 . PubMed PMID: 34289373; PubMed Central PMCID: PMC8362934.","journal-title":"Cell Rep"},{"issue":"4","key":"4467_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/cells10040747","volume":"10","author":"W Piao","year":"2021","unstructured":"Piao W, Kasinath V, Saxena V, Lakhan R, Iyyathurai J, Bromberg JS. LT\u03b2R Signaling Controls Lymphatic Migration of Immune Cells. Cells. 2021;10(4):747. doi:10.3390\/cells10040747 PubMed PMID: 33805271; PubMed Central PMCID: PMC8065509.","journal-title":"Cells"},{"issue":"1","key":"4467_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.immuni.2017.05.008","volume":"47","author":"L Onder","year":"2017","unstructured":"Onder L, M\u00f6rbe U, Pikor N, Novkovic M, Cheng HW, Hehlgans T, et al. Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis. Immunity. 2017;47(1):80\u2013e924. https:\/\/doi.org\/10.1016\/j.immuni.2017.05.008 . PubMed PMID: 28709801.","journal-title":"Immunity"},{"key":"4467_CR24","doi-asserted-by":"publisher","first-page":"736670","DOI":"10.3389\/fimmu","volume":"12","author":"G Vella","year":"2021","unstructured":"Vella G, Guelfi S, Bergers G. High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. Front Immunol. 2021;12:736670. https:\/\/doi.org\/10.3389\/fimmu. 2021.736670 PubMed PMID: 34484246; PubMed Central PMCID: PMC8416033.","journal-title":"Front Immunol"},{"issue":"17","key":"4467_CR25","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","volume":"71","author":"L Martinet","year":"2011","unstructured":"Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678\u201387. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0431 . PubMed PMID: 21846823.","journal-title":"Cancer Res"},{"issue":"11","key":"4467_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.it.2014","volume":"35","author":"MC Dieu-Nosjean","year":"2014","unstructured":"Dieu-Nosjean MC, Goc J, Giraldo NA, Saut\u00e8s-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571\u201380. https:\/\/doi.org\/10.1016\/j.it.2014. 09.006 PubMed PMID: 25443495.","journal-title":"Trends Immunol"},{"issue":"1","key":"4467_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4049\/jimmunol.173.1","volume":"173","author":"T Chtanova","year":"2004","unstructured":"Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1\/Th2 effector cells that provide help for B cells. J Immunol Baltim Md 1950. 2004;173(1):68\u201378. https:\/\/doi.org\/10.4049\/jimmunol.173.1. .68 PubMed PMID: 15210760.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"1","key":"4467_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.immuni.2008.06.001","volume":"29","author":"A Vogelzang","year":"2008","unstructured":"Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity. 2008;29(1):127\u201337. https:\/\/doi.org\/10.1016\/j.immuni.2008.06.001 . PubMed PMID: 18602282.","journal-title":"Immunity"},{"issue":"6","key":"4467_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/0008-5472.CAN-24-2274","volume":"85","author":"T Ninomiya","year":"2025","unstructured":"Ninomiya T, Kemmotsu N, Mukohara F, Magari M, Miyamoto A, Ueda Y, et al. Myeloid Cells Induce Infiltration and Activation of B Cells and CD4\u2009+\u2009T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy. Cancer Res. 2025;85(6):1082\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2274 . PubMed PMID: 39804971.","journal-title":"Cancer Res"},{"issue":"10","key":"4467_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ni.3554","volume":"17","author":"JS Weinstein","year":"2016","unstructured":"Weinstein JS, Herman EI, Lainez B, Licona-Lim\u00f3n P, Esplugues E, Flavell R, et al. TFH cells progressively differentiate to regulate the germinal center response. Nat Immunol. 2016;17(10):1197\u2013205. https:\/\/doi.org\/10.1038\/ni.3554 . PubMed PMID: 27573866; PubMed Central PMCID: PMC5030190.","journal-title":"Nat Immunol"},{"issue":"1","key":"4467_CR31","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41467-021-22300-2","volume":"12","author":"Q Hu","year":"2021","unstructured":"Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12(1):2186. https:\/\/doi.org\/10.1038\/s41467-021-22300-2 . PubMed PMID: 33846305; PubMed Central PMCID: PMC8042001.","journal-title":"Nat Commun"},{"issue":"6","key":"4467_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.medj.2023.04","volume":"4","author":"SY Wu","year":"2023","unstructured":"Wu SY, Zhang SW, Ma D, Xiao Y, Liu Y, Chen L, et al. CCL19\u2009+\u2009dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med N Y N. 2023;4(6):373\u2013e3938. https:\/\/doi.org\/10.1016\/j.medj.2023.04. .008 PubMed PMID: 37201522.","journal-title":"Med N Y N"},{"issue":"1","key":"4467_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.0801986","volume":"183","author":"H Qin","year":"2009","unstructured":"Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, et al. TGF-\u03b2 promotes Th17 cell development through inhibition of SOCS3. J Immunol Baltim Md 1950. 2009;183(1):97\u2013105. https:\/\/doi.org\/10.4049\/jimmunol.0801986 . PubMed PMID: 19535626; PubMed Central PMCID: PMC2851540.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"6","key":"4467_CR34","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-15-2770","volume":"76","author":"LM Jones","year":"2016","unstructured":"Jones LM, Broz ML, Ranger JJ, Ozcelik J, Ahn R, Zuo D, et al. Stat3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 2016;76(6):1416\u201328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2770 . PubMed PMID: 26719528; PubMed Central PMCID: PMC5052827.","journal-title":"Cancer Res"},{"issue":"11","key":"4467_CR35","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.29923","volume":"138","author":"K Banerjee","year":"2016","unstructured":"Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016;138(11):2570\u20138. https:\/\/doi.org\/10.1002\/ijc.29923 . PubMed PMID: 26559373; PubMed Central PMCID: PMC4801660.","journal-title":"Int J Cancer"},{"issue":"10","key":"4467_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers11101479","volume":"11","author":"I Zerdes","year":"2019","unstructured":"Zerdes I, Wallerius M, Sifakis EG, Wallmann T, Betts S, Bartish M, et al. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers. 2019;11(10):1479. https:\/\/doi.org\/10.3390\/cancers11101479 . PubMed PMID: 31581535; PubMed Central PMCID: PMC6827034.","journal-title":"Cancers"},{"issue":"43","key":"4467_CR37","doi-asserted-by":"publisher","first-page":"30082","DOI":"10.1074\/jbc.M","volume":"289","author":"M Snyder","year":"2014","unstructured":"Snyder M, Huang J, Huang XY, Zhang JJ. A signal transducer and activator of transcription 3\u00b7Nuclear Factor \u03baB (Stat3\u00b7NF\u03baB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-\u03b1. J Biol Chem. 2014;289(43):30082\u20139. https:\/\/doi.org\/10.1074\/jbc.M. 114.591719 PubMed PMID: 25213863; PubMed Central PMCID: PMC4208015.","journal-title":"J Biol Chem"},{"key":"4467_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fimmu.2020.00122","volume":"11","author":"A Suryawanshi","year":"2020","unstructured":"Suryawanshi A, Hussein MS, Prasad PD, Manicassamy S. Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity. Front Immunol. 2020;11:122. https:\/\/doi.org\/10.3389\/fimmu.2020.00122 . PubMed PMID: 32132993; PubMed Central PMCID: PMC7039855.","journal-title":"Front Immunol"},{"issue":"1","key":"4467_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41698-024-00579","volume":"8","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, et al. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8(1):73. https:\/\/doi.org\/10.1038\/s41698-024-00579-. w PubMed PMID: 38519580; PubMed Central PMCID: PMC10959936.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"4467_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41423-020-0457-0","volume":"17","author":"L Munoz-Erazo","year":"2020","unstructured":"Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer - considerations for patient prognosis. Cell Mol Immunol. 2020;17(6):570\u20135. https:\/\/doi.org\/10.1038\/s41423-020-0457-0 . PubMed PMID: 32415259; PubMed Central PMCID: PMC7264315.","journal-title":"Cell Mol Immunol"},{"issue":"7791","key":"4467_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8 . PubMed PMID: 31942075; PubMed Central PMCID: PMC8762581.","journal-title":"Nature"},{"issue":"3","key":"4467_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/CMR.0000000000000439","volume":"28","author":"AM Stowman","year":"2018","unstructured":"Stowman AM, Hickman AW, Mauldin IS, Mahmutovic A, Gru AA, Slingluff CL. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 2018;28(3):237\u201345. https:\/\/doi.org\/10.1097\/CMR.0000000000000439 . PubMed PMID: 29538091; PubMed Central PMCID: PMC5912978.","journal-title":"Melanoma Res"},{"issue":"1","key":"4467_CR43","doi-asserted-by":"publisher","first-page":"101961","DOI":"10.1016\/j.xpro.2022.101961","volume":"4","author":"LT Quigley","year":"2023","unstructured":"Quigley LT, Pang L, Tavancheh E, Ernst M, Behren A, Huynh J, et al. Protocol for investigating tertiary lymphoid structures in human and murine fixed tissue sections using OpalTM-TSA multiplex immunohistochemistry. STAR Protoc. 2023;4(1):101961. https:\/\/doi.org\/10.1016\/j.xpro.2022.101961 . PubMed PMID: 36633948; PubMed Central PMCID: PMC9843255.","journal-title":"STAR Protoc"},{"key":"4467_CR44","doi-asserted-by":"publisher","unstructured":"Solis ES, Mart\u00ednez-Romero A, Bras\u00f3-Maristany F, Pascual T, Marin M, Bravo RG et al. 13P A novel H&E-based classification of tertiary lymphoid structures in breast cancer. ESMO Open. 2025;10(Suppl 4):104567. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104567.","DOI":"10.1016\/j.esmoop.2025.104567"},{"issue":"1","key":"4467_CR45","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1038\/s41467-021-26271-2","volume":"12","author":"A Andersson","year":"2021","unstructured":"Andersson A, Larsson L, Stenbeck L, Salm\u00e9n F, Ehinger A, Wu SZ, et al. Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nat Commun. 2021;12(1):6012. https:\/\/doi.org\/10.1038\/s41467-021-26271-2 . PubMed PMID: 34650042; PubMed Central PMCID: PMC8516894.","journal-title":"Nat Commun"},{"issue":"1","key":"4467_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12935-025-03635-y","volume":"25","author":"X Fan","year":"2025","unstructured":"Fan X, Feng D, Wei D, Li A, Wei F, Deng S, et al. Characterizing tertiary lymphoid structures associated single-cell atlas in breast cancer patients. Cancer Cell Int. 2025;25(1):12. https:\/\/doi.org\/10.1186\/s12935-025-03635-y . PubMed PMID: 39806382; PubMed Central PMCID: PMC11727541.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4467_CR47","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/jmri.28900","volume":"59","author":"K Li","year":"2024","unstructured":"Li K, Ji J, Li S, Yang M, Che Y, Xu Z, et al. Analysis of the Correlation and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Radiomics-Clinical Integration Approach. J Magn Reson Imaging JMRI. 2024;59(4):1206\u201317. https:\/\/doi.org\/10.1002\/jmri.28900 . PubMed PMID: 37526043.","journal-title":"J Magn Reson Imaging JMRI"},{"issue":"1","key":"4467_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41698-025-01012-6","volume":"9","author":"Y Lin","year":"2025","unstructured":"Lin Y, Yu Y, Wang Q, Huang K, Guo S, Zhang J, et al. Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer. NPJ Precis Oncol. 2025;9(1):216. https:\/\/doi.org\/10.1038\/s41698-025-01012-6 . PubMed PMID: 40595417; PubMed Central PMCID: PMC12217602.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"4467_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41568-023","volume":"24","author":"H Mai","year":"2024","unstructured":"Mai H, wildDISCO. HD whole-body imaging. Nat Rev Cancer. 2024;24(1):1. https:\/\/doi.org\/10.1038\/s41568-023-. 00640-z PubMed PMID: 37872444.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4467_CR50","doi-asserted-by":"publisher","first-page":"1900508","DOI":"10.1080\/2162402","volume":"10","author":"NJJT Sl","year":"2021","unstructured":"Sl NJJT, Gt N. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Oncoimmunology. 2021;10(1):1900508. https:\/\/doi.org\/10.1080\/2162402. X.2021.1900508 PubMed PMID: 33854820; PubMed Central PMCID: PMC8018489.","journal-title":"Oncoimmunology"},{"issue":"6576","key":"4467_CR51","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419. https:\/\/doi.org\/10.1126\/science.abf. 9419 PubMed PMID: 34990248.","journal-title":"Science"},{"issue":"1","key":"4467_CR52","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/imr.12405","volume":"271","author":"MC Dieu-Nosjean","year":"2016","unstructured":"Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Saut\u00e8s-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev. 2016;271(1):260\u201375. https:\/\/doi.org\/10.1111\/imr.12405 . PubMed PMID: 27088920.","journal-title":"Immunol Rev"},{"issue":"2","key":"4467_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4049\/jimmunol.2000873","volume":"206","author":"LGM van Baarsen","year":"2021","unstructured":"Gago da Gra\u00e7a C, van Baarsen LGM, Mebius RE. Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role. J Immunol. 2021;206(2):273\u201381. https:\/\/doi.org\/10.4049\/jimmunol.2000873 . PubMed PMID: 33397741.","journal-title":"J Immunol"},{"key":"4467_CR54","doi-asserted-by":"publisher","first-page":"1439413","DOI":"10.3389\/fimmu.2024.1439413","volume":"15","author":"M Reste","year":"2024","unstructured":"Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, et al. The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases. Front Immunol. 2024;15:1439413. https:\/\/doi.org\/10.3389\/fimmu.2024.1439413 . PubMed PMID: 39483484; PubMed Central PMCID: PMC11526390.","journal-title":"Front Immunol"},{"key":"4467_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4939-8709","volume":"1845","author":"E Jones","year":"2018","unstructured":"Jones E, Gallimore A, Ager A. Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer. Methods Mol Biol. 2018;1845:99\u2013118. https:\/\/doi.org\/10.1007\/978-1-4939-8709. -2_7 PubMed PMID: 30141010.","journal-title":"Methods Mol Biol"},{"key":"4467_CR56","doi-asserted-by":"publisher","unstructured":"Boissi\u00e8re-Michot F, Chateau MC, Th\u00e9zenas S, Lafont V, Crapez E, Sharma P, et al. Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1507371.","DOI":"10.3389\/fimmu.2024.1507371"},{"key":"4467_CR57","doi-asserted-by":"crossref","unstructured":"Calado DP, Boulat V, Alberts E, Driscoll PC, Hung MS, Cunha A et al. Lactate Blocks Tertiary Lymphoid Structure Formation by Inhibiting B Cell Chemotaxis. bioRxiv. 2025;2025\u201308.","DOI":"10.1101\/2025.08.30.673054"},{"issue":"12Supplement","key":"4467_CR58","first-page":"P2","volume":"31","author":"H Shen","year":"2025","unstructured":"Shen H, Chen Q, Zhang J, Wang S, Zhao J, Zhu C, et al. Abstract P2-05-27: Revealing prognostic subtypes and related model of early-stage TNBC. Clin Cancer Res. 2025;31(12Supplement):P2\u201305.","journal-title":"Clin Cancer Res"},{"issue":"12Supplement","key":"4467_CR59","first-page":"P2","volume":"31","author":"J Sheridan","year":"2025","unstructured":"Sheridan J, Chen JG, Xu J, Ennis C, Kelley E, Kewalramani N, et al. Abstract P2-11-05: Accurate and cost-effective reconstruction of TNBC heterogeneity through 3D digitization of core needle biopsies. Clin Cancer Res. 2025;31(12Supplement):P2\u201311.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4467_CR60","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1309\/AJCPIXUYDVZ0RZ3G","volume":"144","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, et al. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am J Clin Pathol. 2015;144(2):278\u201388. doi:10.1309\/AJCPIXUYDVZ0RZ3G PubMed PMID: 26185313.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"4467_CR61","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00428-015-1861-1","volume":"467","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Kim JY, Song IH, Park IA, Yu JH, Ahn JH, et al. High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. Virchows Arch Int J Pathol. 2015;467(6):701\u20139. https:\/\/doi.org\/10.1007\/s00428-015-1861-1 . PubMed PMID: 26445971.","journal-title":"Virchows Arch Int J Pathol"},{"issue":"2","key":"4467_CR62","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4143\/crt.2016.098","volume":"49","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, Hwang CS, Kim YK, Lee HJ, Ahn SJ, Shin N, et al. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. Cancer Res Treat. 2017;49(2):313\u201321. https:\/\/doi.org\/10.4143\/crt.2016.098 . PubMed PMID: 27456948; PubMed Central PMCID: PMC5398397.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"4467_CR63","first-page":"2705","volume":"36","author":"JY Kim","year":"2016","unstructured":"Kim JY, Heo SH, Song IH, Park IA, Kim YA, Gong G, et al. Activation of the PERK-eIF2\u03b1 Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer. Anticancer Res. 2016;36(6):2705\u201311. PubMed PMID: 27272779.","journal-title":"Anticancer Res"},{"key":"4467_CR64","doi-asserted-by":"publisher","first-page":"155171","DOI":"10.1016\/j.prp.2024.155171","volume":"254","author":"S Dieleman","year":"2024","unstructured":"Dieleman S, Kooreman LFS, van Kuijk SMJ, Zur Hausen A, Smidt ML, Grabsch HI. Germinal centres within tumour positive sentinel lymph nodes are positively associated with tumour infiltrating lymphocytes and tertiary lymphoid structures in breast cancer. Pathol Res Pract. 2024;254:155171. https:\/\/doi.org\/10.1016\/j.prp.2024.155171 . PubMed PMID: 38306861.","journal-title":"Pathol Res Pract"},{"issue":"12Supplement","key":"4467_CR65","first-page":"P5","volume":"31","author":"E Sanfeliu","year":"2025","unstructured":"Sanfeliu E, Martinez-Romero A, Mar\u00edn-Aguilera M, Marco V, Garcia F, Peg V, et al. Abstract P5-07-18: HER2DX assay in HER2-positive (HER2+) breast ductal carcinoma in situ (DCIS). Clin Cancer Res. 2025;31(12Supplement):P5\u201307.","journal-title":"Clin Cancer Res"},{"key":"4467_CR66","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.11.066","volume":"39","author":"P De Silva","year":"2019","unstructured":"De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, et al. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine. 2019;39:226\u201338. PubMed PMID: 30579865; PubMed Central PMCID: PMC6354712.","journal-title":"EBioMedicine"},{"issue":"7","key":"4467_CR67","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/cac2","volume":"45","author":"I Garrido-Cano","year":"2025","unstructured":"Garrido-Cano I, Tapia M, Carbonell J, Pe\u00f1a C, Torres\u2010Ruiz S, \u00c1greda\u2010Roca A, et al. Deciphering the transcriptomic landscape of early HR+\/HER2\u2009\u2013\u2009breast cancer in very young women. Cancer Commun. 2025;45(7):789\u201393. https:\/\/doi.org\/10.1002\/cac2. 70019 PubMed PMID: 40207642; PubMed Central PMCID: PMC12328086.","journal-title":"Cancer Commun"},{"issue":"9","key":"4467_CR68","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24(9):629\u201346. https:\/\/doi.org\/10.1038\/s41568-024-00728-0.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4467_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-025-01754-7","volume":"18","author":"S Deng","year":"2025","unstructured":"Deng S, Chen Y, Song B, Wang H, Huang S, Wu K, et al. Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities. J Hematol OncolJ Hematol Oncol. 2025;18(1):97. https:\/\/doi.org\/10.1186\/s13045-025-01754-7.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"4467_CR70","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12943-024-02126-4","volume":"23","author":"S Li","year":"2024","unstructured":"Li S, Zhang N, Zhang H, Yang Z, Cheng Q, Wei K, et al. Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients. Mol Cancer. 2024;23:216. https:\/\/doi.org\/10.1186\/s12943-024-02126-4 . PubMed PMID: 39350165; PubMed Central PMCID: PMC11441145.","journal-title":"Mol Cancer"},{"issue":"1","key":"4467_CR71","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s43856-025-00865-z","volume":"5","author":"AH R\u00f8ssevold","year":"2025","unstructured":"R\u00f8ssevold AH, Tekpli X, Lingj\u00e6rde OC, Russnes HG, Vallon-Christersson J, Borgen E, et al. High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis. Commun Med. 2025;5(1):234. https:\/\/doi.org\/10.1038\/s43856-025-00865-z . PubMed PMID: 40523912; PubMed Central PMCID: PMC12170890.","journal-title":"Commun Med"},{"key":"4467_CR72","doi-asserted-by":"publisher","first-page":"105082","DOI":"10.1016\/j.critrevonc.2025.105082","volume":"218","author":"D Stylianakis","year":"2026","unstructured":"Stylianakis D, Benjamin HA, Martella S, De Silva P, Stylianakis I, Denaro N, et al. Spatial multiomics of the breast tumour microenvironment: State of the field, advancements and clinical implementation promises. Crit Rev Oncol Hematol. 2026;218:105082. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105082 . PubMed PMID: 41389952.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"4467_CR73","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","volume":"68","author":"M Sofopoulos","year":"2019","unstructured":"Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother CII. 2019;68(11):1733\u201345. https:\/\/doi.org\/10.1007\/s00262-019-02407-8 . PubMed PMID: 31598757; PubMed Central PMCID: PMC11028375.","journal-title":"Cancer Immunol Immunother CII"},{"key":"4467_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12885-015-1116-1","volume":"15","author":"SL Figenschau","year":"2015","unstructured":"Figenschau SL, Fismen S, Fenton KA, Fenton C, Mortensen ES. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer. 2015;15:101. https:\/\/doi.org\/10.1186\/s12885-015-1116-1 . PubMed PMID: 25884667; PubMed Central PMCID: PMC4357183.","journal-title":"BMC Cancer"},{"issue":"2","key":"4467_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4143\/crt.2016.215","volume":"49","author":"IH Song","year":"2017","unstructured":"Song IH, Heo SH, Bang WS, Park HS, Park IA, Kim YA, et al. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2017;49(2):399\u2013407. https:\/\/doi.org\/10.4143\/crt.2016.215 . PubMed PMID: 27488875; PubMed Central PMCID: PMC5398384.","journal-title":"Cancer Res Treat"},{"issue":"18","key":"4467_CR76","doi-asserted-by":"publisher","first-page":"e129641","DOI":"10.1172\/jci.insight.129641","volume":"5","author":"S Garaud","year":"2019","unstructured":"Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 2019;5(18):e129641. https:\/\/doi.org\/10.1172\/jci.insight.129641 . PubMed PMID: 31408436; PubMed Central PMCID: PMC6795287.","journal-title":"JCI Insight"},{"key":"4467_CR77","doi-asserted-by":"publisher","first-page":"868155","DOI":"10.3389\/fimmu.2022.868155","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Liu J, Han Y, Deng Y, Li J, Jiang Y. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer. Front Immunol. 2022;13:868155. https:\/\/doi.org\/10.3389\/fimmu.2022.868155 . PubMed PMID: 35664009; PubMed Central PMCID: PMC9161084.","journal-title":"Front Immunol"},{"issue":"7","key":"4467_CR78","doi-asserted-by":"publisher","first-page":"e009232","DOI":"10.1136\/jitc-2024-009232","volume":"12","author":"YY Zhao","year":"2024","unstructured":"Zhao YY, Fan Z, Tao BR, Du ZG, Shi ZF. Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis. J Immunother Cancer. 2024;12(7):e009232. https:\/\/doi.org\/10.1136\/jitc-2024-009232 . PubMed PMID: 39067874; PubMed Central PMCID: PMC11284839.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4467_CR79","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/cells12081176","volume":"12","author":"AC Barb","year":"2023","unstructured":"Barb AC, Pasca Fenesan M, Pirtea M, Margan MM, Tomescu L, Melnic E, et al. Tertiary Lymphoid Structures (TLSs) and Stromal Blood Vessels Have Significant and Heterogeneous Impact on Recurrence, Lymphovascular and Perineural Invasion amongst Breast Cancer Molecular Subtypes. Cells. 2023;12(8):1176. https:\/\/doi.org\/10.3390\/cells12081176 . PubMed PMID: 37190085; PubMed Central PMCID: PMC10136904.","journal-title":"Cells"},{"issue":"16","key":"4467_CR80","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.3390\/cancers16162895","volume":"16","author":"N Thomas","year":"2024","unstructured":"Thomas N, Garaud S, Langouo M, Sofronii D, Boisson A, De Wind A, et al. Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer. Cancers. 2024;16(16):2895. https:\/\/doi.org\/10.3390\/cancers16162895 . PubMed PMID: 39199667; PubMed Central PMCID: PMC11352458.","journal-title":"Cancers"},{"issue":"9","key":"4467_CR81","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/modpathol.2017.43","volume":"30","author":"L Buisseret","year":"2017","unstructured":"Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, et al. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 2017;30(9):1204\u201312. https:\/\/doi.org\/10.1038\/modpathol.2017.43 . PubMed PMID: 28621322.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"issue":"8","key":"4467_CR82","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cac2","volume":"43","author":"F Bertucci","year":"2023","unstructured":"Bertucci F, De Nonneville A, Finetti P, Mamessier E. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer. Cancer Commun. 2023;43(8):943\u20136. https:\/\/doi.org\/10.1002\/cac2. 12447 PubMed PMID: 37278484; PubMed Central PMCID: PMC10397558.","journal-title":"Cancer Commun"},{"issue":"1","key":"4467_CR83","doi-asserted-by":"publisher","first-page":"13542","DOI":"10.1038\/s41598-023-40042-7","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang L, Gong S, Pang L, Zhang S, Zhang X, He W. Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer. Sci Rep. 2023;13(1):13542. https:\/\/doi.org\/10.1038\/s41598-023-40042-7 . PubMed PMID: 37598257; PubMed Central PMCID: PMC10439954.","journal-title":"Sci Rep"},{"issue":"7","key":"4467_CR84","doi-asserted-by":"publisher","first-page":"112808","DOI":"10.1016\/j.isci.2025.112808","volume":"28","author":"RH Mebane","year":"2025","unstructured":"Mebane RH, Noel T, Ing N, Gouin KH, Shah A, Zitser D, et al. Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. iScience. 2025;28(7):112808. https:\/\/doi.org\/10.1016\/j.isci.2025.112808 . PubMed PMID: 40599321; PubMed Central PMCID: PMC12209978.","journal-title":"iScience"},{"issue":"1","key":"4467_CR85","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1038\/s41598-024-64042-3","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Wang S, Lv S, Liu X, Li W, Song Y, et al. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs. Sci Rep. 2024;14(1):13432. https:\/\/doi.org\/10.1038\/s41598-024-64042-3 . PubMed PMID: 38862586; PubMed Central PMCID: PMC11166640.","journal-title":"Sci Rep"},{"issue":"6","key":"4467_CR86","doi-asserted-by":"publisher","first-page":"e1583547","DOI":"10.1080\/2162402X.2019.1583547","volume":"8","author":"G Morcrette","year":"2019","unstructured":"Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, et al. APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology. 2019;8(6):e1583547. 2019.1583547 PubMed PMID: 31069152; PubMed Central PMCID: PMC6492969.","journal-title":"Oncoimmunology"},{"issue":"6","key":"4467_CR87","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29(6):1424\u201336. https:\/\/doi.org\/10.1038\/s41591-023-02369-6 . PubMed PMID: 37280275.","journal-title":"Nat Med"},{"issue":"1","key":"4467_CR88","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1078-0432.CCR-24-1594","volume":"31","author":"T Lanickova","year":"2025","unstructured":"Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al. Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1\u2009+\u2009CD8+ T Cells in Metastatic Ovarian Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2025;31(1):164\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1594 . PubMed PMID: 39163092; PubMed Central PMCID: PMC11701433.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"4467_CR89","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019 . PubMed PMID: 25517616; PubMed Central PMCID: PMC5155593.","journal-title":"Immunity"},{"issue":"12","key":"4467_CR90","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1\u2009+\u2009T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022;40(12):1600\u2013e161810. PubMed PMID: 36423635; PubMed Central PMCID: PMC9899876.","journal-title":"Cancer Cell"},{"issue":"1","key":"4467_CR91","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12967-024-05409","volume":"22","author":"H Sadeghirad","year":"2024","unstructured":"Sadeghirad H, Monkman J, Tan CW, Liu N, Yunis J, Donovan ML, et al. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. J Transl Med. 2024;22(1):677. https:\/\/doi.org\/10.1186\/s12967-024-05409-. y PubMed PMID: 39049036; PubMed Central PMCID: PMC11267849.","journal-title":"J Transl Med"},{"issue":"8","key":"4467_CR92","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41590-021-00958-6","volume":"22","author":"S Eschweiler","year":"2021","unstructured":"Eschweiler S, Clarke J, Ram\u00edrez-Su\u00e1stegui C, Panwar B, Madrigal A, Chee SJ, et al. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nat Immunol. 2021;22(8):1052\u201363. https:\/\/doi.org\/10.1038\/s41590-021-00958-6 . PubMed PMID: 34168370; PubMed Central PMCID: PMC8434898.","journal-title":"Nat Immunol"},{"key":"4467_CR93","doi-asserted-by":"publisher","first-page":"1507371","DOI":"10.3389\/fimmu.2024.1507371","volume":"15","author":"F Boissi\u00e8re-Michot","year":"2024","unstructured":"Boissi\u00e8re-Michot F, Chateau MC, Th\u00e9zenas S, Lafont V, Crapez E, Sharma P, et al. Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol. 2024;15:1507371. https:\/\/doi.org\/10.3389\/fimmu.2024.1507371 . PubMed PMID: 39723208; PubMed Central PMCID: PMC11669358.","journal-title":"Front Immunol"},{"issue":"4","key":"4467_CR94","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","volume":"10","author":"J Sawada","year":"2022","unstructured":"Sawada J, Hiraoka N, Qi R, Jiang L, Fournier-Goss AE, Yoshida M, et al. Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival. Cancer Immunol Res. 2022;10(4):468\u201381. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0369 . PubMed PMID: 35201289; PubMed Central PMCID: PMC8976767.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4467_CR95","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","volume":"15","author":"NG Ciavattone","year":"2025","unstructured":"Ciavattone NG, Bevoor A, Farfel A, Rehman A, Ho KKY, Rock EC, et al. Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy. Sci Rep. 2025;15(1):5204. https:\/\/doi.org\/10.1038\/s41598-025-89882-5 . PubMed PMID: 39939722; PubMed Central PMCID: PMC11822021.","journal-title":"Sci Rep"},{"issue":"7","key":"4467_CR96","doi-asserted-by":"publisher","first-page":"e009232","DOI":"10.1136\/jitc-2024-009232","volume":"12","author":"YY Zhao","year":"2024","unstructured":"Zhao YY, Fan Z, Tao BR, Du ZG, Shi ZF. Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis. J Immunother Cancer. 2024;12(7):e009232. https:\/\/doi.org\/10.1136\/jitc-2024-009232 . PubMed PMID: 39067874; PubMed Central PMCID: PMC11284839.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4467_CR97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/path.5080","volume":"245","author":"B He","year":"2018","unstructured":"He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, et al. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol. 2018;245(2):209\u201321. https:\/\/doi.org\/10.1002\/path.5080 . PubMed PMID: 29603739; PubMed Central PMCID: PMC6737176.","journal-title":"J Pathol"},{"key":"4467_CR98","doi-asserted-by":"publisher","first-page":"1334408","DOI":"10.3389\/fimmu.2023.1334408","volume":"14","author":"D Wang","year":"2023","unstructured":"Wang D, Huang L, Qian D, Cao Y, Wu X, Xu P, et al. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma. Front Immunol. 2023;14:1334408. https:\/\/doi.org\/10.3389\/fimmu.2023.1334408 . PubMed PMID: 38259481; PubMed Central PMCID: PMC10800908.","journal-title":"Front Immunol"},{"issue":"1","key":"4467_CR99","doi-asserted-by":"publisher","first-page":"e13740","DOI":"10.1111\/cpr.13740","volume":"58","author":"MJ Zhang","year":"2025","unstructured":"Zhang MJ, Lin WP, Wang Q, Wang S, Song A, Wang YY, et al. Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10\/CXCR3 to boost antitumor immunity. Cell Prolif. 2025;58(1):e13740. https:\/\/doi.org\/10.1111\/cpr.13740 . PubMed PMID: 39219056; PubMed Central PMCID: PMC11693575.","journal-title":"Cell Prolif"},{"issue":"16","key":"4467_CR100","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, et al. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8\u2009+\u2009T-cell Infiltration. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(16):4556\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2821 . PubMed PMID: 28468947; PubMed Central PMCID: PMC5599263.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04467-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:16:33Z","timestamp":1789002993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04467-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04467-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"366"}}